Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The report highlights the promising advancements in the company's product pipeline, particularly LBL-034 and LBL-024, which are positioned to redefine treatment paradigms in multiple myeloma and other cancers [3][4] - The company has a strong financial position with sufficient cash reserves to support multiple research pipelines, bolstered by recent fundraising efforts [6] - Revenue projections indicate a gradual increase, with expected revenues of 260 million in 2025, 284 million in 2026, and 467 million in 2027, reflecting a growth rate of 64% in 2027 [5][6] Summary by Sections Product Development - LBL-034 has shown a 90.9% overall response rate (ORR) in a specific dosage group for treating relapsed/refractory multiple myeloma, demonstrating "Best-in-class" potential compared to competitors [3] - LBL-024 has effectively addressed liver toxicity issues associated with 4-1BB agonists, with a reported ≥3 grade liver enzyme elevation of only 1.3% across approximately 450 enrolled patients [4] - Initial clinical data for LBL-024 in non-small cell lung cancer (NSCLC) shows an ORR of 50% and a disease control rate (DCR) of 94.4%, indicating significant therapeutic potential [4] Financial Projections - The company is projected to have total revenues of 260 million, 284 million, and 467 million from 2025 to 2027, with year-over-year growth rates of 9% and 64% respectively [5] - The net profit attributable to the parent company is expected to be -416 million, -518 million, and -719 million for the same period, with a declining growth rate [5][6] - The gross margin is anticipated to be 100% in 2025 and 2026, decreasing to 93.68% in 2027 [5] Cash Position - As of the first half of 2025, the company had cash and cash equivalents of 422 million, supplemented by net proceeds of 1.363 billion HKD from its initial public offering [6]

Core Insights - The core viewpoint of the report is that Heng Rui Pharmaceutical has demonstrated significant profit growth in the first three quarters of 2025, driven by innovative drug development and accelerated external collaborations [1] Financial Performance - In the first three quarters of 2025, Heng Rui Pharmaceutical achieved a net profit attributable to shareholders of 5.751 billion yuan, representing a year-on-year increase of 24.50% [1] - In Q3 alone, the net profit attributable to shareholders was 1.301 billion yuan, showing a year-on-year growth of 9.53% [1] Growth Drivers - The rapid growth in performance is attributed to two main factors: 1. Continuous realization of results from innovative drug research and development, leading to increased market penetration of core products [1] 2. Accelerated external licensing collaborations, contributing to incremental revenue from upfront payments and milestone achievements [1] Innovation and R&D - The company has an efficient innovative pipeline, with a continuous expansion of its core product matrix [1] - Multiple new technology platforms, including a new molecular model platform and an AI drug development platform, are being iterated to support ongoing source innovation [1] - The strong independent R&D capabilities of the company position it well for future innovative drug results to enter international markets, potentially leading the wave of domestic innovative drugs going abroad [1] Valuation - Based on the PE valuation method and comparable company valuation levels, the company is given a target price of 78.52 yuan, corresponding to a 52 times price-to-earnings ratio for 2026 [1] - The report maintains a "Buy" rating for the company [1]

流动性方面，港股创新药精选ETF盘中换手7.74%，成交4223.87万元。拉长时间看，截至11月10日，港股创新药精选ETF近1年日均成交1.20亿元。 据报道，11月10日，华润三九公告，与琅钰集团、Bioproject 达成重磅合作，拿下发作性睡病创新药铧可思(替洛利生片)在中国大陆开发与商业化权益。华 润三九这款创新药的获得，不仅将为患者带来安全治疗新选择，更标志着华润三九在罕见病赛道的布局迈出关键一步。 消息方面，近日，第76届美国肝病研究协会（AASLD）年会在美国华盛顿开幕。由上海贺普药业研发的乙肝创新药贺普拉肽临床研究取得突破性进展，以 大会报告形式公布了治疗慢性乙肝II期随机双盲临床试验结果。据介绍，该创新药通过独特的病毒进入阻断独特机制，在II期临床试验中显示可逆转"大三 阳"乙肝患者对干扰素治疗的耐药性，在部分患者实现cccDNA清除，达到国际公认乙肝治愈最高标准-灭菌性治愈（sterilising cure）。 截至2025年11月11日 14:02，恒生港股通创新药精选指数下跌0.94%。成分股方面涨跌互现，联邦制药领涨1.92%，MIRXES-B上涨1.74%，三生制药上涨 0.9 ...

Core Viewpoint - Real Bio Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange for the third time, with CICC as its sole sponsor, after previous unsuccessful attempts in August 2022 and February 2025 [1] Group 1: Company Overview - Real Bio, established in 2012, focuses on the development, manufacturing, and commercialization of innovative drugs for viral infections, tumors, and cardiovascular diseases [1] - The company's core product, Azvudine, has received conditional approval in China for treating HIV and COVID-19, and is exploring indications for tumors [1] Group 2: Financial Performance - In 2023, the company generated revenue of 344 million yuan, with 99.2% coming from collaboration with Fosun Pharma; however, revenue dropped over 30% in 2024 due to decreased demand post-pandemic, with revenue further declining to 16.53 million yuan in the first half of 2025 [1][2] - Research and development expenses for 2023, 2024, and the first half of 2025 were 238 million yuan, 151 million yuan, and 54.05 million yuan, respectively [2] - The company has not yet achieved profitability, reporting pre-tax losses of 784 million yuan, 40.04 million yuan, and 165 million yuan for the years 2023, 2024, and the first half of 2025 [2] Group 3: Market Strategy and Partnerships - Real Bio's primary customer in 2023 was Fosun Pharma, accounting for 100% of sales; however, the partnership ended in September 2024, leading to new collaborations with 65 offline distributors and 9 online distributors for Azvudine sales [2] - The company has completed two rounds of financing, raising 713 million yuan, with a post-money valuation of 3.56 billion yuan after the B round in 2022 [3] - The IPO proceeds will primarily fund the development of new indications for Azvudine, particularly in tumor combination therapies, as well as clinical advancement of core pipelines and expansion of commercialization channels [3]

Group 1 - The core point of the article is that Federal Pharmaceutical (03933) has seen a nearly 3% increase in its stock price following the announcement of successful Phase II clinical trials for its innovative drug TUL01101 for moderate to severe atopic dermatitis in adults [1] - The company reported that TUL01101 met its expected goals in the Phase II clinical study, which supports its progression to the next phase of clinical research [1] - Federal Pharmaceutical has completed communication with regulatory authorities regarding TUL01101's End of Phase 2 (EOP2) and is initiating Phase III clinical trials in China for moderate to severe atopic dermatitis patients [1]

Group 1: Flu Season Overview - The flu season has entered an outbreak phase in both Japan and China, with Japan reporting over 57,000 cases in the week ending November 2, doubling from the previous week, marking 11 consecutive weeks of increase [1] - In China, respiratory infectious diseases are on the rise, with flu-like cases reported at 5.1% in northern provinces, higher than the previous week and the same period in the last three years [1] Group 2: Drug Development and Market Demand - The flu virus strain this year is primarily the H3N2 subtype, leading to lower immunity in the population compared to last year's H1N1 strain, creating a demand for effective new treatments [2] - "Anglavei" (brand name: Anruiwei®) from Zhongsheng Pharmaceutical is the first oral drug targeting RNA polymerase PB2 for type A influenza, approved in May 2023, showing rapid symptom relief and low resistance [2][3] - Anglavei has demonstrated significant efficacy against both H1 and H3 strains, with a median symptom relief time of 38.83 hours and a rapid reduction in viral load within 24 hours [3] Group 3: Company Performance and Strategic Outlook - Zhongsheng Pharmaceutical reported a revenue of 1.908 billion yuan and a net profit of 250 million yuan for the first three quarters of 2025, with a year-on-year increase of 68.4% [5] - The company is expanding the application of Anglavei to children, with promising results from phase II clinical trials, aiming to fill a gap in pediatric treatment [3][5] - The strategic focus on innovative drug development and a diversified pipeline positions Zhongsheng Pharmaceutical for long-term growth and market competitiveness [6]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company reported a revenue of 3.923 billion yuan for Q1-Q3 2025, a year-on-year increase of 1.67%, and a net profit of 388 million yuan, up 5.84% year-on-year [1]. - In Q3 2025, the company achieved a revenue of 1.288 billion yuan, a year-on-year increase of 5.01%, but a quarter-on-quarter decrease of 1.60% [1]. - The innovative drugs, Yili Shou and Yinikang, saw a combined sales revenue growth of 147.04% in Q1-Q3 2025, with Yili Shou's shipments increasing by 77.99% and Yinikang's by 315.76% [2]. - The clinical trial of the traditional Chinese medicine, Duanjin Jiedu Capsule, successfully demonstrated superior efficacy in preventing relapse compared to the placebo group [3]. Financial Performance - The company expects revenues of 6.101 billion, 7.137 billion, and 8.284 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 606 million, 819 million, and 1.061 billion yuan for the same years [6]. - The company reported a net profit of 84 million yuan in Q3 2025, a decrease of 25.64% year-on-year and 44.09% quarter-on-quarter [1]. - The self-owned pharmaceutical formulation products generated revenue of 2.969 billion yuan in Q1-Q3 2025, reflecting an 11.07% year-on-year increase [2]. Clinical Trials and Product Development - The A-319 (CD3&CD19 TCE bispecific antibody) showed good tolerance in clinical trials, with preliminary efficacy indicating a reduction in SLEDA I-2K scores [4][5]. - The Duanjin Jiedu Capsule demonstrated a significant increase in the negative rate of urine opioid substances, achieving a 95.2% negative rate compared to 68.6% in the placebo group [3]. Market Position and Valuation - The company has a total market capitalization of approximately 15.983 billion yuan, with a circulating market value of about 11.057 billion yuan [7]. - The company's earnings per share (EPS) is projected to be 0.50 yuan in 2025, with a price-to-earnings (P/E) ratio of 26.36 [10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 自願性公告 全球創新產品萊特靈®(Ryaltris®)複方鼻噴劑在中國獲批上市 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，由 Glenmark Specialty S.A. (「Glenmark」)研發的全球創新藥 Ryaltris® 複方鼻噴劑(「GSP 301 NS」或「萊特靈® 」)近日獲得中華人民共和國國家藥品監督管 理局(「藥監局」)頒發的藥品註冊證書，用於治療成人和兒童的過敏性鼻炎(「AR」)， 且在藥品審評過程中未收到補充資料通知，實現「零發補」獲批上市，這是本集團在呼 吸及危重症領域的又一項重大研發進展。本集團於二零一九年二月與 Glenmark 訂立了 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][7] Core Views - The company's revenue for the first three quarters of 2025 reached 231.88 billion yuan, a year-on-year increase of 14.85%, with net profit attributable to the parent company at 57.51 billion yuan, up 24.50% year-on-year [11] - The growth is driven by the continuous release of innovative drug research results and accelerated overseas licensing cooperation, contributing to incremental performance [11] - The company has strengthened its innovative pipeline, with significant product approvals and a robust pipeline in various therapeutic areas [11] Financial Performance Summary - Revenue (in million yuan): - 2023A: 22,820 - 2024A: 27,985 - 2025E: 34,184 - 2026E: 38,303 - 2027E: 43,925 - Year-on-year growth rates: 2024A: 22.6%, 2025E: 22.2%, 2026E: 12.0%, 2027E: 14.7% [6][13] - Net profit (in million yuan): - 2023A: 4,302 - 2024A: 6,337 - 2025E: 8,755 - 2026E: 10,043 - 2027E: 11,403 - Year-on-year growth rates: 2024A: 47.3%, 2025E: 38.2%, 2026E: 14.7%, 2027E: 13.5% [6][13] - Earnings per share (in yuan): - 2023A: 0.65 - 2024A: 0.95 - 2025E: 1.32 - 2026E: 1.51 - 2027E: 1.72 [6][13] Strategic Developments - The company has achieved significant overseas licensing agreements, with over 800 million USD in upfront payments in the first three quarters of 2025 [11] - Recent collaborations include agreements with GSK, Glenmark, and Braveheart Bio, indicating a strong push towards internationalization [11] - The company is focusing on expanding its innovative drug portfolio, with multiple new drug applications accepted by NMPA [11]

Core Viewpoint - The company's performance is driven by the high-quality growth from innovative drug releases and accelerated overseas expansion, achieving a revenue of 23.188 billion yuan in the first three quarters of 2025, a year-on-year increase of 14.85%, and a net profit attributable to the parent company of 5.751 billion yuan, up 24.50% year-on-year [1] Group 1: Financial Performance - In Q3 alone, the company achieved a revenue of 7.427 billion yuan, a year-on-year increase of 12.72%, with a net profit of 1.301 billion yuan, up 9.53% year-on-year [1] - The high-speed growth in performance is attributed to two main factors: continuous realization of innovative drug research results and accelerated external licensing cooperation, contributing to upfront payments and milestone revenues [1] Group 2: Innovation Pipeline - The company continues to strengthen growth driven by innovation, with the approval of the first domestic EZH2 inhibitor and the first self-developed oral triple compound for diabetes in Q3, which will accelerate sales potential as these products are launched [1] - A total of 13 new drug applications were accepted by NMPA in the first three quarters, with 8 applications in Q3, including significant progress on the GLP-1/GIP dual-target weight loss drug HRS9531 [1] - The company is enhancing its research pipeline across various therapeutic areas, including oncology, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience [1] Group 3: Business Development and Collaborations - The company is accelerating its global presence through business development (BD) transactions and self-research overseas, with over 800 million USD in overseas licensing upfront payments in the first three quarters [2] - In Q3, the company secured three external licensing agreements, including a 500 million USD upfront payment with GSK for 12 innovative drugs, and additional agreements with Glenmark and BraveheartBio totaling 180 million and 65 million USD upfront payments, respectively [2] - The strong independent research and development capabilities position the company to lead the wave of domestic innovative drugs going overseas [2] Group 4: Earnings Forecast and Investment Recommendations - Due to the continuous overseas expansion of innovative drugs and exceeding expectations in licensing income, the company's EPS forecasts for 2025-2027 have been raised to 1.32, 1.51, and 1.72 yuan, respectively [3] - Based on the PE valuation method and comparable company valuation levels, a target price of 78.52 yuan is set for 2026, maintaining a "buy" rating [3]